A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Eric Angevin,Gianluca Spitaleri,Jordi Rodon,Katia Dotti,Nicolas Isambert,Stefania Salvagni,Victor Moreno,Sylvie Assadourian, Corinne Gomez, Marzia Harnois,Antoine Hollebecque,Analia Azaro,Alice Hervieu,Karim Rihawi,Filippo De Marinis

European Journal of Cancer（2017）

引用 30|浏览15

暂无评分

摘要

•SAR125844 was well tolerated in patients with solid tumours and MET dysregulation.•SAR125844 was efficacious in MET-amplified tumours with partial responses observed.•Significant antitumour activity was observed in patients with MET-amplified NSCLC.

查看译文

关键词

MET-inhibitor,Advanced solid tumours,NSCLC,MET-amplified,Phase I,Dose escalation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要